Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 21Unknown 8Terminated 6Recruiting 5Active not recruiting 4Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Drug Therapy 4Cisplatin 4Chemoradiotherapy 4lenvatinib 3camrelizumab 3Specimen Handling 3Paclitaxel 3Oxaliplatin 3Carboplatin 3toripalimab 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Patient Navigation 2Methods 2Leucovorin 2Laparoscopy 2Fluorouracil 2Fluorodeoxyglucose F18 2Educational Status 2Early Intervention, Educational 2Colonoscopy 2Capecitabine 2Biopsy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tislelizumab 1sintilimab 1pembrolizumab 1nimotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Dexamethasone × Gastrointestinal × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡